Systematic review on curative effects of oxiracetam and piracetam in treatment of cerebral organic syndrome

WANG Jing; ZHANG Jie; ZHOU Jie

doi:10.3969/j.issn.1674-4055.2016.02.09

Abstract：Objective To review systematically the curative effects and safety of oxiracetam and piracetam in treatment of cerebral organic syndrome.Methods The databases of WanFang Database, CNKI, VIP Database, PubMed, EMbase, MERSTR Database (FMRS, Cochrane Library, ACP Journal Club, etc.) were retrieved with computer assisted literature retrospective and online inquiry for collecting randomized controlled trials (RCT) about the treatment of cerebral organic syndrome with oxiracetam and piracetam published in China and other countries from database establishment time to Dec. 31, 2014. After extracting data and quality reviewing, the included RCT was given a Meta-analysis by using RevMan5.0 software.Results There were totally 9 RCT included (1347 cases) involved 675 cases treated with oxiracetam and 672 treated with piracetam. The results of Meta-analysis showed that the improvement of Mini-Mental Status Examination (MMSE) was better in oxiracetam group than that in piracetam group (WMD=3.89, 95%CI: 3.32~4.45,P<0.01), the improvement of Glasgow Coma Scale (GCS) was better in oxiracetam group than that in piracetam group (WMD=1.83, 95%CI: 1.28~2.39,P<0.01), and the improvement of National Institute of Health Stroke Scale (NIHSS) was better in oxiracetam group than that in piracetam group (WMD=-3.75, 95%CI: -7.70~ -4.18, P<0.01). The difference in the incidence of major adverse cardiovascular events (MACE) had no statistical significance between oxiracetam group and piracetam group (OR=0.71, 95%CI: 0.37~1.37,P>0.05).Conclusion Oxiracetam is superior to piracetam in treatment of cerebral organic syndrome (scores of MMSE, GCS and NIHSS), and they have no significant difference in the incidence of MACE.